Logo image of COV.PA

COVIVIO (COV.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:COV - FR0000064578 - REIT

53.9 EUR
-0.05 (-0.09%)
Last: 12/9/2025, 5:36:15 PM
Fundamental Rating

3

COV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 40 industry peers in the Diversified REITs industry. There are concerns on the financial health of COV while its profitability can be described as average. COV has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year COV was profitable.
COV had a positive operating cash flow in the past year.
Of the past 5 years COV 4 years were profitable.
In the past 5 years COV always reported a positive cash flow from operatings.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

COV has a Return On Assets (1.63%) which is comparable to the rest of the industry.
COV has a Return On Equity (5.08%) which is in line with its industry peers.
COV has a Return On Invested Capital (3.21%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for COV is in line with the industry average of 3.46%.
The 3 year average ROIC (2.97%) for COV is below the current ROIC(3.21%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

Looking at the Profit Margin, with a value of 30.46%, COV is in line with its industry, outperforming 47.50% of the companies in the same industry.
COV's Profit Margin has declined in the last couple of years.
COV has a Operating Margin of 57.81%. This is in the lower half of the industry: COV underperforms 65.00% of its industry peers.
In the last couple of years the Operating Margin of COV has remained more or less at the same level.
The Gross Margin of COV (74.42%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, COV has more shares outstanding
The number of shares outstanding for COV has been increased compared to 5 years ago.
The debt/assets ratio for COV has been reduced compared to a year ago.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

COV has an Altman-Z score of 0.53. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
COV has a Altman-Z score of 0.53. This is in the lower half of the industry: COV underperforms 72.50% of its industry peers.
The Debt to FCF ratio of COV is 28.44, which is on the high side as it means it would take COV, 28.44 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 28.44, COV is not doing good in the industry: 72.50% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.07 is on the high side and indicates that COV has dependencies on debt financing.
COV's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. COV is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.44
Altman-Z 0.53
ROIC/WACC0.56
WACC5.76%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 0.76 indicates that COV may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.76, COV is in the better half of the industry, outperforming 65.00% of the companies in the same industry.
A Quick Ratio of 0.69 indicates that COV may have some problems paying its short term obligations.
The Quick ratio of COV (0.69) is better than 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.98% over the past year.
Measured over the past years, COV shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.39% on average per year.
COV shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.96%.
The Revenue has been growing slightly by 1.17% on average over the past years.
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%

3.2 Future

COV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.58% yearly.
The Revenue is expected to grow by 2.72% on average over the next years.
EPS Next Y5.08%
EPS Next 2Y3.46%
EPS Next 3Y3.58%
EPS Next 5YN/A
Revenue Next Year-1.22%
Revenue Next 2Y1.48%
Revenue Next 3Y2.72%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

4

4. Valuation

4.1 Price/Earnings Ratio

COV is valuated reasonably with a Price/Earnings ratio of 11.69.
Based on the Price/Earnings ratio, COV is valued a bit cheaper than 70.00% of the companies in the same industry.
COV is valuated cheaply when we compare the Price/Earnings ratio to 26.28, which is the current average of the S&P500 Index.
COV is valuated reasonably with a Price/Forward Earnings ratio of 11.26.
COV's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.52, COV is valued rather cheaply.
Industry RankSector Rank
PE 11.69
Fwd PE 11.26
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, COV is valued a bit cheaper than the industry average as 62.50% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COV indicates a slightly more expensive valuation: COV is more expensive than 62.50% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.29
EV/EBITDA 16.8
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COV does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.3
PEG (5Y)N/A
EPS Next 2Y3.46%
EPS Next 3Y3.58%

4

5. Dividend

5.1 Amount

COV has a Yearly Dividend Yield of 6.37%, which is a nice return.
COV's Dividend Yield is a higher than the industry average which is at 5.96.
Compared to an average S&P500 Dividend Yield of 2.31, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.37%

5.2 History

The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

92.95% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP92.95%
EPS Next 2Y3.46%
EPS Next 3Y3.58%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (12/9/2025, 5:36:15 PM)

53.9

-0.05 (-0.09%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)07-21 2025-07-21/bmo
Earnings (Next)02-18 2026-02-18/amc
Inst Owners41.72%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.02B
Revenue(TTM)1.37B
Net Income(TTM)417.86M
Analysts80
Price Target64.71 (20.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.37%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.95%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.43%
PT rev (3m)0.2%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)-1.33%
Valuation
Industry RankSector Rank
PE 11.69
Fwd PE 11.26
P/S 4.39
P/FCF 15.29
P/OCF 5.99
P/B 0.73
P/tB 0.76
EV/EBITDA 16.8
EPS(TTM)4.61
EY8.55%
EPS(NY)4.78
Fwd EY8.88%
FCF(TTM)3.52
FCFY6.54%
OCF(TTM)8.99
OCFY16.69%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)2.3
PEG (5Y)N/A
Graham Number87.41
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
FCFM 28.68%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexgc growth 3Y12.16%
ROICexgc growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.44
Debt/EBITDA 9.39
Cap/Depr 417.19%
Cap/Sales 44.51%
Interest Coverage 250
Cash Conversion 106.87%
Profit Quality 94.14%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.53
F-Score7
WACC5.76%
ROIC/WACC0.56
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
EPS Next Y5.08%
EPS Next 2Y3.46%
EPS Next 3Y3.58%
EPS Next 5YN/A
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%
Revenue Next Year-1.22%
Revenue Next 2Y1.48%
Revenue Next 3Y2.72%
Revenue Next 5YN/A
EBIT growth 1Y-0.73%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year12.84%
EBIT Next 3Y8.07%
EBIT Next 5Y7.52%
FCF growth 1Y42.08%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y30.56%
OCF growth 3Y12.5%
OCF growth 5Y4.86%

COVIVIO / COV.PA FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status of COVIVIO (COV.PA) stock?

ChartMill assigns a valuation rating of 4 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the earnings growth outlook for COVIVIO?

The Earnings per Share (EPS) of COVIVIO (COV.PA) is expected to grow by 5.08% in the next year.


Can you provide the dividend sustainability for COV stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.95%.